GlassScriptPhysician profile
Erica K Linnell
NPI 1700037769
$6,435.28
in general payments reported to CMS, 2019-2025
27 companies · $1,560 in 2025
The $1,560 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $393 · 2021: $765 · 2022: $900 · 2023: $877 · 2024: $1,174 · 2025: $1,560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,610.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,610.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,596.23 | 2019-2025 | Dysport, Aklief |
| Genzyme Corporation | $1,309.60 | 2019-2025 | |
| Abbvie INC. | $1,212.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.31 | 2019-2025 | Libtayo, Dupixent |
| Revance Therapeutics, INC. | $265.39 | 2025 | Daxxify |
| Novartis Pharmaceuticals Corporation | $237.59 | 2024-2025 | |
| Incyte Corporation | $177.38 | 2023-2025 | Opzelura |
| Ucb, INC. | $153.94 | 2021-2024 | Bimzelx |
| Allergan, INC. | $148.69 | 2022 | |
| Janssen Biotech, INC. | $146.33 | 2021-2025 | Tremfya |
| Almirall LLC | $145.33 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $124.04 | 2022-2025 | Sotyktu |
| Pfizer INC. | $103.77 | 2019-2025 | |
| Leo Pharma INC. | $79.16 | 2021-2025 | Anzupgo |
| Solta Medical, A Division of Bausch Health US, LLC | $76.68 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Sun Pharmaceutical Industries INC. | $63.56 | 2023-2024 | Absorica Ld, Winlevi |
| Botanix Sb INC | $52.72 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $46.61 | 2021 | |
| Mayne Pharma Commercial LLC | $23.83 | 2020 | |
| Prugen, INC. Pharmaceuticals | $20.66 | 2019 | |
| Biofrontera INC. | $19.65 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Sandoz INC. | $18.54 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.73 | 2024 | Zoryve |
| Merz North America, INC. | $16.98 | 2024 | |
| Dermira, INC. | $16.21 | 2019 | |
| Merck Sharp & Dohme LLC | $14.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Linnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.